United States: Supreme Court's Request For Views Of The United States On Cert. Petition In Lamictal "Reverse-Payment" Case Flags Potential Issues For Practitioners

Last Updated: June 15 2016
Article by Robert P. Reznick

On Monday, June 7, the Supreme Court requested the views of the Solicitor General in connection with a petition for certiorari filed by the U.S. subsidiary of GlaxoSmithKline plc ("GSK") in SmithKline Beecham Corp. v. King Drug Co. of Florence, No. 15-1055.  The Supreme Court's request seems less directed to rethinking its seminal ruling in FTC v. Actavis on the lawfulness of "reverse-payment" settlements of Hatch-Waxman cases than to a concern that, in some specific ways, its decision may have created some unintended consequences.

King Drug involved the settlement of patent infringement litigation over a brand-name drug used to treat epilepsy and bipolar disorder, Lamictal®, brought by GSK against Teva Pharmaceuticals under the framework of the Hatch-Waxman Act.  Among other features, the settlement gave Teva a license under GSK's patent and NDA for Lamictal® to enter the market prior to expiration of the patent in suit, and GSK agreed not to authorize another generic entrant during the period in which Teva would not face competition from any other FDA-approved generics.  Patent- and NDA-licensed generic entrants are referred to as "authorized generics" ("AGs"), as compared with generics that enter via the ANDA approval process.  The settlement term in which GSK agreed not to license its NDA to another generic manufacturer is colloquially referred to as a "No-AG agreement."  While estimates varied and issues of causation remained, there was no dispute that an additional Lamictal® AG would earn GSK some marginal revenue and reduce both Teva's volume of sales and the prevailing market price.

In its 2013 decision in FTC v. Actavis, the Supreme Court held that certain "reverse-payment" settlements of Hatch-Waxman patent infringement cases could violate the antitrust laws, and were subject to review under the rule of reason.  As most relevant here, the Court concluded that antitrust concerns could be raised where the branded drug's manufacturer settled the case by providing the generic's manufacturer a "large and unexplained payment" tied to a delay in entry from the date of settlement.  The Court's concern was that the payment might be an improper agreement to delay entry and split the proceeds of an otherwise unjustified agreement to maintain the patent monopoly in a situation where there is an invalid, or arguably invalid, patent.

In 2015, a panel of the Third Circuit found the GSK-Teva settlement potentially to constitute a "large and unexplained payment," reversing the district court's dismissal of the case on grounds that the non-cash No-AG agreement could not be within the scope of Actavis.  The court of appeals did not dispute GSK's right to license its patent for Lamictal® as such, just its possible use as a means to eliminate a challenge to the patent: "[T]he fact that the Patent Act expressly authorizes licensing does not necessarily mean it also authorizes reverse payments to prevent generic competition."

At first blush, the decision does not appear controversial, as courts other than the district court below had uniformly found that the "payment" required by Actavis need not be in cash (although a number of courts, including the First Circuit in Loestrin, have required that a complaint provide a basis for quantifying the non-cash compensation allegedly transferred).  And, specifically, no court had found No-AG agreements outside the scope of Actavis.  Nor is there a conflict on this point between the two courts of appeals to have construed Actavis.  All that said, what motivated the Supreme Court to seek the views of the Solicitor General?  We can think of a few possible explanations.

First, the Lamictal case might be a good and much-needed vehicle for addressing the limitations of Actavis.  That opinion was rife with references to factors that would cause a reverse-payment settlement not to implicate antitrust law—including the definition of a "payment," the meaning of a "large" payment, what explanations can support all or some of an otherwise "large" reverse payment, and the range of pro-competitive effects that would be relevant in a rule of reason analysis.  But the Court explained almost none of them further, and expressly left the lower courts to fill in the blanks.  The Federal Trade Commission, for its part, through litigation and amicus briefs has been busy trying to push back virtually any suggestion of limits at all.  More than a dozen Hatch-Waxman settlements have been in litigation since Actavis was decided, and defining the scope of the Supreme Court's decision has been a struggle.  No-AG Agreements test a number of those limits.  Notably, they do not involve a direct transfer of compensation from Brand to Generic—although they can be seen both as a decision to forego income from an authorized generic and to permit the Generic to earn more in the marketplace.  Still, we doubt the fact of confusion and uncertainty, standing alone, would warrant an inquiry as to the views of the United States.

A more likely reason is another limit that the Court suggested but did not flesh out—that the antitrust laws not be applied so as to render unlawful "commonplace," "familiar," or "traditional" means of settling patent infringement cases.  GSK and Teva argued that one such form is the grant of an exclusive patent license (here, a semi-exclusive one because the Brand retains a right to use the patent).  Indeed, the National Association of Manufacturers filed an amicus brief to underscore the point that the Third Circuit had read Actavis so as to permit virtually any antitrust challenge to a settlement incorporating an exclusive license to survive a motion to dismiss, no matter what industry was involved.

A related point made by those favoring Supreme Court review was that a patentholder's right to license its patent is specifically authorized by  35 U.S.C. § 261.  Beyond the argument that the antitrust laws should not be read to circumscribe so closely a specific statutory grant, the Court in Actavis itself distinguished the dissent as having failed to "identify any patent statute that it understands to grant [a right to enter into reverse-payment settlements] to a patentee."  A similar point was made by counsel for the FTC at oral argument in Actavis, who distinguished "reverse payment" settlements from licenses "expressly authorized by the Patent Act."

Another interesting issue is that the 180-day exclusivity period is a financial incentive that Congress intended to encourage companies like Teva to challenge the patents of branded drugs (or to design around the patents).  In the early days of discussion about authorized generics, some (including some at the FTC) argued that Congress intended the 180-day exclusivity period to reward such patent challengers with six months of freedom from generic competition of any kind, including from AGs.  To the extent the purpose of the statutory exclusivity period is viewed in this way, an interesting argument can be made that the No-AG agreement merely preserves in place a benefit that Congress intended the generic manufacturer receive, and thus cannot be an element of an antitrust violation.  Not many cases discuss the point, but some hold that governmentally-enacted financial benefits (such as tariffs or subsidies by foreign governments) do not make the competitive playing field any less level even though they may permit certain companies to price at levels that others cannot profitably match.  See, e.g., Outboard Marine Corp. v. Pezetel, 461 F. Supp. 384, 400 (D. Del. 1978) ("The antitrust laws were not intended as a sanctuary for those who cannot compete against lower prices be they the result of simple efficiency, economies of scale, cheap labor, technological expertise or anything other than commercially mischievous conduct. Thus, although plaintiff is injured by defendant's capability to offer lower prices as a result of foreign government subsidies to [plaintiff's competitor], the Court concludes that the antitrust laws do not provide a remedy for such loss.").

It seems to us that the Supreme Court might well want to know whether the Solicitor General believes that the Third Circuit's ruling will put a cloud over patent infringement settlements via exclusive or semi-exclusive license, and whether 35 U.S.C. § 261 provides some sort of safe harbor for No-AG agreements.  The FTC recently brought its first action based on the presence of a No-AG agreement in the Endo case, and that may suggest the Solicitor General will be unlikely to view the Third Circuit's decision with alarm and go out of his or her way to seek further review.

The SG's response is unlikely to arrive before the Fall, so a ruling on the petition will not likely occur until well into the Court's new term.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
26 Sep 2018, Seminar, Tokyo, Japan

Orrick’s Global Japan Practice is hosting a series of “Orrick Library” seminars to explore legal issues in various fields in Japan as well as the United States, Asia and Europe

26 Sep 2018, Conference, New York, United States

Employment Partner, Mandy Perry and Chair of Orrick's Global Employment Law Practice, Mike Delikat will be participating in the Global Business Protections 2018: International Restrictive Covenants and Confidential Information Conference.

10 Oct 2018, Conference, Florida, United States
Julie Totten is Program Chair of this year’s conference, Lynne Hermle is speaking on women in the courtroom, boardroom, and c-suite, and Erin Connell is speaking on pay equity and pay transparency.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions